Director of Vera Therapeutics Sells More Than $34 Million of Company Stock

Table of contents

Director of Vera Therapeutics Sells More Than  Million of Company Stock

© Reuters.

Vera Therapeutics, Inc. (NASDAQ: VERA), a pharmaceutical preparations company, announced a significant stock sale by Director Maha Katabi. According to the latest filings, Katabi, who holds a position at Sofinnova Investments, sold a total of $34,099,582 worth of Class A common stock in a series of transactions.

The sales occurred over several days, with shares selling at prices ranging from $40.50 to $46.18. The largest single-day sale occurred on March 22, where shares were sold at an average price of $40.51, contributing substantially to the total amount sold.

Investors might note that the transactions were made indirectly through Sofinnova Venture Partners X, LP, indicating Katabi’s association with the entity that owns the shares. The sales would be comparable to a prior purchase of Class A common stock by Sofinnova Venture Partners X, LP, which could potentially invoke Section 16(b) of the Exchange Act relating to short-term profits.

The filings also included a commitment from Katabi to return all profits attributable to matching the aforementioned purchase with reported sales, pursuant to the agreement with Vera Therapeutics.

Following these transactions, the reported shares held by Sofinnova Venture Partners X, LP have decreased, but they still hold a substantial stake in the company. The precise number of shares sold at each price level within the ranges provided was made available upon request, in accordance with footnotes in the SEC filing.

Investors who track insider transactions as part of their investment strategy may find this development noteworthy, as it reflects a significant change in ownership structure by a key director of Vera Therapeutics.

InvestingPro Insights

Amid recent insider transactions at Vera Therapeutics, Inc. (NASDAQ:VERA), the company’s financial health and stock performance indicators offer additional insight. With a market capitalization of $2.16 billion, the company stands out in the pharmaceutical preparations sector. Despite the significant insider selling, Vera Therapeutics saw a Robust return of 448.34% over the past yearwhich could demonstrate strong investor confidence or reflect market reactions to the evolution of its pipeline and strategic decisions.

From an investment perspective, it is important to note that analysts don’t expect Vera Therapeutics to be profitable this year, as evidenced by a negative P/E ratio of -18.45, which later adjusted to -22.52 for the trailing twelve months as of Q4 2023. This indicates that the company is currently not generating profits relative to its share price. In addition, the company Price/book ratio is sitting at a high of 21.26, suggesting that the market is valuing the company significantly above its net asset value, a point of interest for value investors.

Investors considering Vera Therapeutics should be aware that the company does not pay dividends, which could influence the investment strategy of those seeking regular income from their investments. However, the company’s liquidity exceeds its short-term obligations, which may provide some assurance regarding its near-term financial stability.

For those looking for a more in-depth analysis, there are 11 more InvestPro Advice available at This guidance may provide a more complete understanding of Vera Therapeutics’ financial health and market position. Don’t forget to use the promo code PRONEWS24 to get an additional 10% off a Pro and Pro+ annual or bi-annual subscription, enriching your investment strategy with valuable insights.

This article was generated with the support of AI and reviewed by an editor. For more information, consult our General Terms and Conditions.

Source Reference

Latest stories